Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T28352 |
PDE9-IN-(S)-C33
(S)-C33 |
PDE | Metabolism |
PDE9-IN-(S)-C33 ((S)-C33) 是一种有效的选择性 PDE9 抑制剂 (IC50 = 11 nM)。 PDE9-IN-(S)-C33 可用于中枢神经系统疾病和糖尿病的相关研究。 | |||
T12389 |
PDE-9 inhibitor
|
Others | Others |
PDE-9 inhibitor is used for treatment neurodegenerative diseases. | |||
T12395 |
PDE9-IN-1
|
PDE | Metabolism |
PDE9-IN-1 是一种选择性和口服生物可利用的 PDE9A 抑制剂(IC50 为 8.7 nM)。 | |||
T61833 |
Tovinontrine
IMR-687 |
PDE | Metabolism |
Tovinontrine (IMR-687) 是一种针对镰状细胞病治疗设计的强效且选择性的磷酸二酯酶-9 (PDE9) 抑制剂。其展现出高效能,对PDE9A1和PDE9A2的IC 50 值分别为8.19 nM和9.99 nM [1]。 | |||
T38899 |
Irsenontrine
E2027,Irsenontrine |
||
Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases. | |||
T24163 |
IMR687
IMR-687,IMR 687 |
||
IMR687 is a PDE9 inhibitor that slows or stops the hydrolysis of cGMP. IMR687 can be regarded as a highly promising drug against Alzheimer's for improving memory. | |||
T39108 |
Irsenontrine maleate
E2027 maleate |
||
Irsenontrine (E2027) maleate is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9). It can be utilized in the study of neurological diseases. | |||
T61770 |
(R)-Irsenontrine
|
||
(R)-Irsenontrine ((R)-E2027) 是Irsenontrine 的 R 型异构体,是一种有效的磷酸二酯酶 9 (PDE9) 抑制剂,抑制其IC50值为 0.041 μM。(R)-Irsenontrine 可用于神经系统疾病的研究。 | |||
T81534 |
PDE11A4-IN-1
|
||
PDE11A4-IN-1 (compound 23b) 是一种选择性的 PDE11A4 抑制剂,具有 12 nM 的 IC50。该化合物相对于 PDE1、PDE2、PDE7、PDE8 和 PDE9 显示出较高的选择性。 |